文献速递乳腺癌

年轻BRCA携带者乳腺癌的临床行为及诊断前知晓胚系BRCA状态的影响

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status.
PubMed 文献 · J Clin Oncol · 2025-02-24

这项国际多中心回顾性队列研究纳入4,752例40岁及以下诊断I-III期浸润性乳腺癌的胚系BRCA1/2致病/可能致病变异携带者,比较BRCA1与BRCA2携带者的肿瘤特征及诊断前 versus 诊断时基因检测与预后的关联。BRCA1携带者激素受体阴性和高级别肿瘤更常见;诊断前检测者肿瘤更小、淋巴结受累更少、治疗负担更低,未调整OS更优,但调整肿瘤分期等混杂因素后无统计学显著性。

要点

  • BRCA1携带者较BRCA2更常见激素受体阴性(74.4% v 15.5%)和高级别肿瘤(77.5% v 49.1%)。
  • 诊断前检测者较诊断时检测者肿瘤更小(T1 61.3% v 32.4%)、淋巴结受累更少(N0 65.9% v 50.8%)。
  • 诊断前检测者未调整OS更优(HR 0.61,95%CI 0.40-0.92),调整混杂因素后无统计学显著性(HR 0.74,95%CI 0.47-1.15)。

核心结论

  • 该全球研究提供了年轻BRCA1与BRCA2携带者乳腺癌不同临床行为的证据。
  • 在健康个体中识别BRCA致病变异与更早期乳腺癌诊断、更低治疗负担及更优的未调整OS相关。

研究设计与样本

  • 国际、多中心、基于医院的回顾性队列研究,纳入4,752例胚系BRCA1或BRCA2致病/可能致病变异携带者。
  • 患者于2000年1月至2020年12月期间在78个中心诊断为I-III期浸润性乳腺癌,诊断年龄40岁或以下(ClinicalTrials.gov标识:NCT03673306)。

主要发现

  • BRCA1携带者(n=3,069)较BRCA2携带者(n=1,683)更常见激素受体阴性肿瘤(74.4% v 15.5%)和高级别肿瘤(77.5% v 49.1%)。
  • BRCA1与BRCA2携带者观察到相似结局,但无病生存事件随时间变化的模式和风险不同。
  • 诊断前检测者(n=411)较诊断时检测者(n=1,671)肿瘤更小(T1:61.3% v 32.4%)、淋巴结受累更少(N0:65.9% v 50.8%)。
  • 诊断前检测者较少接受化疗(84.4% v 92.9%)和腋窝清扫(37.5% v 47.4%)。
  • 诊断前检测者总生存更优(未调整HR 0.61,95%CI 0.40-0.92),但调整肿瘤分期等潜在混杂因素后无统计学显著性(调整HR 0.74,95%CI 0.47-1.15)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene (BRCA1 v BRCA2) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS: This was an international, multicenter, hospital-based, retrospective cohort study that included 4,752 patients harboring germline pathogenic/likely pathogenic variants (PVs) in BRCA1 or BRCA2, who were diagnosed with stage I-III invasive breast cancer at 40 years or younger between January 2000 and December 2020 in 78 centers worldwide (ClinicalTrials.gov identifier: NCT03673306). RESULTS: Compared with BRCA2 carriers (n = 1,683), BRCA1 carriers (n = 3,069) had more frequently hormone receptor-negative (74.4% v 15.5%) and high-grade (77.5% v 49.1%) tumors. Similar outcomes were observed in BRCA1 and BRCA2 carriers but with a different pattern and risk of disease-free survival events over time. Compared with patients tested for BRCA at diagnosis (ie, between 2 months before and up to 6 months after diagnosis; n = 1,671), those tested before diagnosis (ie, any time up to 2 months before diagnosis; n = 411) had smaller tumors (T1: 61.3% v 32.4%), less nodal involvement (N0: 65.9% v 50.8%), less frequently received chemotherapy (84.4% v 92.9%), and axillary dissection (37.5% v 47.4%). Patients tested before diagnosis had better overall survival (OS; unadjusted hazard ratio [HR], 0.61 [95% CI, 0.40 to 0.92]); however, this result lost statistical significance after adjustment for potential confounders including tumor stage (adjusted HR, 0.74 [95% CI, 0.47 to 1.15]). CONCLUSION: This global study provides evidence on the different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers. Identifying a BRCA PV in healthy individuals was associated with earlier-stage breast cancer diagnosis and lower treatment burden, as well as better unadjusted OS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lambertini M, Blondeaux E, Tomasello LM, et al. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. J Clin Oncol. 2025. PMID: 39993249. doi:10.1200/JCO-24-01334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。